Our Motto
Full-service Independent Global CRO
Cyntax Health Projects is a leading Contract Research Organization (CRO) delivering end-to-end clinical research services, with operational bases in Pakistan and collaborations extending across the UK, USA, Europe, and South Asia. We specialize in providing comprehensive clinical research solutions to the biopharmaceutical, biotechnology, and medical device industries, supporting studies across all therapeutic areas and phases of development. Our GCP-certified team ensures scientific rigor, regulatory compliance, and operational excellence throughout every project, from protocol development and regulatory submissions to site management, monitoring, data management, and pharmacovigilance. At Cyntax, we are committed to accelerating drug development by delivering high-quality, reliable data to support evidence-based decision-making and bring innovative therapies to patients globally.
Our Broad Range of Specialized Services
Clinical Trial Services
Quality Assurance in Clinical Research
Real World Evidence and Outcomes Research
Remote Decentralized Research Services
Our Values
Patient Safety at Core of Our Trials
Clinical research industry has come a long way from viewing patients as mere “subjects” to playing an integral part in the success of clinical trials. Subject and Patient safety is of utmost importance for us and we take all measure in terms of infrastructure and resources to ensure the same.
Latest Blog Posts
In the ever-evolving world of healthcare innovation, Artificial Intelligence (AI) is rapidly reshaping the clinical research landscape. From drug discovery to patient recruitment, and from real-time data analysis to predictive modeling, AI is helping global clinical trials become faster, more efficient, and patient-centric.
In cancer clinical trials, the shift toward patient-centric research has made Patient-Reported Outcomes (PROs) a vital data source. As oncology becomes more personalized and outcomes-based, understanding how to collect, interpret, and act on PRO data is essential for sponsors, investigators, and regulatory bodies alike.
In May 2023, the U.S. Food and Drug Administration (FDA) released an updated draft guidance on Decentralized Clinical Trials (DCTs)—a major step toward reimagining how clinical research is designed, conducted, and monitored in the digital era.